非肿瘤适应证近端股骨假体关节成形术的五年结局
回顾性分析79例患者共80例非肿瘤适应证近端股骨假体关节成形术,平均随访5年。31.6%发生并发症,5年假体生存率87%(95%CI 76%至98%),平均牛津髋关节评分28分。作者推荐继续用于非肿瘤适应证包括假体周围感染。
要点
- 非肿瘤适应证近端股骨假体5年生存率87%(95%CI 76%至98%),平均OHS 28分。
- 25例(31.6%)发生并发症,最常见为感染9例和脱位3例。
- 感染适应证者假体生存和结局较差,但40例中33例(82.5%)感染根除。
核心结论
- 作者推荐继续将近端股骨假体用于非肿瘤适应证,包括假体周围感染。
研究设计与样本
- 回顾性综述纳入79例患者共80例非肿瘤适应证近端股骨假体,平均随访5年,评估并发症率、生存率和平均牛津髋关节评分。
- 手术时平均年龄69岁(28至93岁),髋部既往手术平均2.4次(0至17次)。
主要发现
- 所有患者均实现保肢。
- 25例患者(25例假体,31.6%)发生并发症,最常见为感染(9例)和脱位(3例)。
- 18例假体(22%)需再次手术,其中9例为翻修手术。
- 假体5年生存率为87%(95%CI 76%至98%),平均牛津髋关节评分为28分(4至48分)。
- 感染适应证者假体生存和结局较差,但40例中33例(82.5%)感染根除。
关键数值与推荐
- 最常见适应证为假体周围感染(40例)、假体周围骨折(12例)和近端股骨骨折或复杂创伤内固定失败(11例)。
临床怎么用
- 作者推荐继续将近端股骨假体用于非肿瘤适应证,包括假体周围感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A possible solution for the management of proximal femoral bone loss is a modular femoral endoprosthesis (EPR). Although the outcome of EPRs in tumour surgery has been well described, the outcome of their use in revision hip surgery has received less attention. The aim of this study was to describe the outcome of using EPR for non-neoplastic indications. METHODS: A retrospective review of 79 patients who underwent 80 EPRs for non-neoplastic indications was performed, including the rates of complication and survival and the mean Oxford Hip Scores (OHS), at a mean of five years post-operatively. The mean age at the time of surgery was 69 years (28 to 93) and the mean number of previous operations on the hip was 2.4 (0 to 17). The most common indications for EPR implantation were periprosthetic joint infection (PJI) (n = 40), periprosthetic fracture (n = 12) and failed osteosynthesis of a proximal femoral fracture or complex trauma (n = 11). RESULTS: Salvage was achieved in all patients. A total of 25 patients (25 EPRs, 31.6%) had a complication, the most common being infection (n = 9) and dislocation (n = 3). Further surgery was required for 18 EPRs (22%), nine of which were revision procedures. The five year survival of the EPR was 87% (95%CI: 76% to 98%). The mean OHS was 28 (4 to 48). Inferior survival and outcomes were seen in EPRs which were performed for the treatment of infection. However, the eradication of infection was achieved in 33 of the 40 (82.5%) which were undertaken for this indication. CONCLUSION: We recommend the continued use of proximal femoral EPRs for non-neoplastic indications, including PJI. Cite this article: Bone Joint J 2016;98-B:1463-70.
引用
- Grammatopoulos G, Alvand A, Martin H, et al. Five-year outcome of proximal femoral endoprosthetic arthroplasty for non-tumour indications. Bone Joint J. 2016. PMID: 27803221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。